Medicine Personal Statementfor Oxford, Cambridge & Imperial

When the first reports of the Pfizer-BioNTech Covid-19 vaccine were followed by headlines on emergency authorisation, I was less struck by the speed than by the argument around it. People around me took that speed as proof that corners had been cut. I wanted to know what had allowed scientists and regulators to move quickly without lowering the standard of evidence. Reading about mRNA vaccines led me first to the immune response: how antigen presentation, clonal selection and memory-cell formation allow a molecular instruction to produce longer-term protection. What began as an attempt to answer a family argument became a harder question about medicine: how doctors act when evidence is strong enough to matter, but not complete enough to remove doubt. That is what continues to draw me to medicine. I want to study a subject that demands both precision and restraint, where scientific understanding has to be turned into decisions and conversations patients can use.

My studies have prepared me for medicine by showing me how scientific ideas become clinical problems. In Biology, cell signalling and homeostasis became much more meaningful when we studied insulin signalling. I was interested in how a disrupted pathway can be tracked biochemically yet still be impossible to separate from a patient's daily life. A raised glucose level is a measurement, but managing diabetes also depends on whether someone can sustain routines, interpret symptoms and trust advice. To understand how evidence is judged in practice, I read Trisha Greenhalgh's How to Read a Paper. Her focus on study design, bias and applicability made me return to the vaccine debate more carefully. A large trial can be rigorous and still leave open questions about representation and which outcomes matter most to patients. My EPQ developed that further. I asked how emergency vaccine approval should balance speed, safety and public trust, and compared phase III efficacy data for the Pfizer-BioNTech and Moderna vaccines with MHRA explanations of rolling review and post-authorisation monitoring through the Yellow Card scheme. The project taught me that good evidence is not a fixed label. The trials were robust, but they were designed under pressure, reported different endpoints and could not answer every long-term question people were asking in real time. Revising my argument also forced me to think more carefully about trust, because my first draft treated vaccine hesitancy mainly as a failure of scientific literacy. I came to see that mistrust can also grow from previous experiences of institutions, not just misunderstanding of data.